Avapritinib in unresectable or metastatic gastrointestinal stromal tumor with PDGFRA exon 18 mutation: safety and efficacy

References

• Helman LJ, Meltzer P. Mechanisms of sarcoma development. Nat Rev Cancer. 2003 Sep;3(9):685–694.
   PubMed Web of Science ®Google Scholar
• Serrano C, George S. Gastrointestinal stromal tumor: challenges and opportunities for a new decade. Clin Cancer Res off J Am Assoc Cancer Res. 2020 Oct 1;26(19):5078–5085.
   PubMed Web of Science ®Google Scholar
• Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors [research support, non-U.S. Gov’t]. Science. 1998 Jan 23;279(5350):577–580.
   PubMed Web of Science ®Google Scholar
• Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors [research support, non-u.s. gov’t research support, U.S. Gov’t, Non-P.H.S.]. Science. 2003 Jan 31;299(5607):708–710.
   PubMed Web of Science ®Google Scholar
• Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors [clinical trial multicenter study randomized controlled trial research support, non-u.s. gov’t research Support, U.S. Gov’t, Non-P.H.S.]. New Engl J Med. 2002 Aug 15;347(7):472–480.
   PubMed Web of Science ®Google Scholar
• Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial [multicenter study randomized controlled trial research support, non-U.S. gov’t research support, U.S. Gov’t, Non-P.H.S.]. Lancet 2006 Oct 14;368(9544):1329–1338.
   PubMed Web of Science ®Google Scholar
• Demetri GD, Reichardt P, Kang YK, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial [clinical trial, phase iii multicenter study randomized controlled trial research support, N.I.H., extramural research support, Non-U.S. Gov’t]. Lancet. 2013 Jan 26;381(9863):295–302.
   PubMed Web of Science ®Google Scholar
• Blay JY, Serrano C, Heinrich MC, et al. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial [clinical trial, phase iii multicenter study randomized controlled trial research support, non-U.S. Gov’t]. Lancet Oncol. 2020 Jul;21(7):923–934.
   PubMed Web of Science ®Google Scholar
• Heinrich MC, Jones RL, von Mehren M, et al. Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial [clinical trial, phase i multicenter study research support, non-U.S. Gov’t]. Lancet Oncol. 2020 Jul;21(7):935–946.
   PubMed Web of Science ®Google Scholar
• Corless CL, Schroeder A, Griffith D, et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib [research support, U.S. Gov’t, Non-P.H.S. Review]. J Clin Oncol. 2005 Aug 10;23(23):5357–5364.
   PubMed Web of Science ®Google Scholar
• Cassier PA, Fumagalli E, Rutkowski P, et al. Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era. Clin Cancer Res off J Am Assoc Cancer Res. 2012 Aug 15;18(16):4458–4464.
   PubMed Web of Science ®Google Scholar
• Wozniak A, Rutkowski P, Schoffski P, et al. Tumor genotype is an independent prognostic factor in primary gastrointestinal stromal tumors of gastric origin: a european multicenter analysis based on ConticaGIST [Multicenter Study Research Support, Non-U.S. Gov’t]. Clin Cancer Res. 2014 Dec 1;20(23):6105–6116.
   PubMed Web of Science ®Google Scholar
• Blanke CD, Demetri GD, von Mehren M, et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT [clinical trial, phase ii multicenter study randomized controlled trial research support, U.S. Gov’t, Non-P.H.S.]. J Clin Oncol. 2008 Feb 1;26(4):620–625.
   PubMed Web of Science ®Google Scholar
• Casali PG, Zalcberg J, Le Cesne A, et al. Ten-year progression-free and overall survival in patients with unresectable or metastatic gi stromal tumors: long-term analysis of the european organisation for research and treatment of cancer, italian sarcoma group, and australasian gastrointestinal trials group intergroup phase iii randomized trial on imatinib at two dose levels. J Clin Oncol. 2017 Mar;35(15):1713–1720.
   PubMed Web of Science ®Google Scholar
• Gajiwala KS, Wu JC, Christensen J, et al. KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients. Proceedings of the National Academy of Sciences of the United States of America. 2009 Feb 3;106( 5):1542–1547.
   Google Scholar
• Evans EK, Gardino AK, Kim JL, et al. A precision therapy against cancers driven by KIT/PDGFRA mutations. Sci Transl Med. 2017 Nov 1;9(414):414.
   Web of Science ®Google Scholar
• Jones RL, Serrano C, von Mehren M, et al. Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: long-term efficacy and safety data from the NAVIGATOR phase I trial. Eur J Cancer. 2021 Mar;145:132–142.
   PubMed Web of Science ®Google Scholar
• Joseph CP, Abaricia SN, Angelis MA, et al. Optimal avapritinib treatment strategies for patients with metastatic or unresectable gastrointestinal stromal tumors. Oncologist. 2021 Apr;26(4):e622–e631.
   PubMed Web of Science ®Google Scholar
• Tannock IF, Ahles TA, Ganz PA, et al. Cognitive impairment associated with chemotherapy for cancer: report of a workshop. J Clin Oncol. 2004 Jun 1;22(11):2233–2239.
   PubMed Web of Science ®Google Scholar
• Ferguson RJ, Manculich J, Snitz B, et al. Cognitive impairment and treatment effects among gastrointenstinal stromal tumor survivors: results of a large online survey. ASCO annual meeting. J clin oncol. 2019;37(15_suppl):e23092–e23092. 2019.
   Web of Science ®Google Scholar
• Grunewald S, Klug LR, Muhlenberg T, et al. Resistance to Avapritinib in PDGFRA-driven gist is caused by secondary mutations in the PDGFRA kinase domain. Cancer Discov. 2020 Sep;24.
   Web of Science ®Google Scholar
• Heinrich MC, Corless CL, Blanke CD, et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors [clinical trial, phase ii randomized controlled trial research support, non-U.S. Gov’t]. J Clin Oncol. 2006 Oct 10;24(29):4764–4774.
   PubMed Web of Science ®Google Scholar
• Heinrich MC, Maki RG, Corless CL, et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor [clinical trial, phase i clinical trial, phase ii research support, n.i.h., extramural research support, non-U.S. gov’t research support, U.S. Gov’t, Non-P.H.S.]. J Clin Oncol. 2008 Nov 20;26(33):5352–5359.
   PubMed Web of Science ®Google Scholar
• Serrano C, Fletcher JA. Overcoming heterogenity in imatinib-resistant gastrointestinal stromal tumor [Editorial]. Oncotarget. 2019 Oct 29;10(59):6286–6287.
   PubMedGoogle Scholar
• Serrano C, Marino-Enriquez A, Tao DL, et al. Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, Non-P.H.S.]. Br J Cancer. 2019 Mar;120(6):612–620.
   PubMed Web of Science ®Google Scholar
• Reichardt P, Kang YK, Rutkowski P, et al. Clinical outcomes of patients with advanced gastrointestinal stromal tumors: safety and efficacy in a worldwide treatment-use trial of sunitinib. Cancer. 2015 May 1;121(9):1405–1413.
   PubMed Web of Science ®Google Scholar
• Schuetze SM, Bolejack V, Thomas DG, et al. Association of dasatinib with progression-free survival among patients with advanced gastrointestinal stromal tumors resistant to imatinib. JAMA Oncol. 2018 Jun 1;4(6):814–820.
   PubMed Web of Science ®Google Scholar
• Janku F, Abdul Razak AR, Chi P, et al. Switch Control Inhibition of KIT and PDGFRA in patients with advanced gastrointestinal stromal tumor: a phase i study of ripretinib. J Clin Oncol. 2020 Oct 1;38(28):3294–3303.
   PubMed Web of Science ®Google Scholar
• Smith BD, Kaufman MD, Lu WP, et al. Ripretinib (DCC-2618) is a switch control kinase inhibitor of a broad spectrum of oncogenic and drug-resistant KIT and PDGFRA variants. Cancer Cell. 2019 May 13;35(5):738–751 e9.
   PubMed Web of Science ®Google Scholar
• Casali PG, Abecassis N, Bauer S, et al. Gastrointestinal stromal tumours: ESMO-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up [practice guideline review]. Ann Oncol. 2018 Oct;29(Suppl 4):iv68–iv78.
   PubMedGoogle Scholar
• von Mehren M, Randall RL, Benjamin RS, et al. Soft tissue sarcoma, version 2.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2018 May;16(5):536–563.
   PubMed Web of Science ®Google Scholar
• Florindez J, Trent J. Low frequency of mutation testing in the united states: an analysis of 3866 GIST patients. Am J Clin Oncol. 2020 Apr;43(4):270–278.
   PubMed Web of Science ®Google Scholar
• George S, Jones RL, Bauer S, et al. Avapritinib in patients with advanced gastrointestinal stromal tumors following at least three prior lines of therapy. Oncologist. 2021 Apr;26(4):e639–e649.
   PubMed Web of Science ®Google Scholar